In what looms as a sub saharan David v. Goliath battle, microcap gold explorer Cassius Mining (ASX: CMD) has served notice to the Government of the Republic of Ghana for breaches of their licencing agreement, with claims amounting to AUD $430 million. Whilst the explorer boasts a market cap of just $1.7m at its current
Read More
Two of the world’s leading payment processing companies have joined forces to launch a new Visa issuing business in the Asia-Pacific region with Australian fintech company Novatti Group (ASX: NOV) partnering with Decta, a leading payments processor in Europe. The partnership leverages two of the company’s core strengths with Novatti holding a Visa Principal Issuer
Read More
Artificial intelligence company SenSen Networks (ASX: SNS) is poised to play a key role in the City of Las Vegas’ plans to become a smart city by 2025 having won a $2.5 million contract to provide the city with AI smart city software, SenSen’s first in the United States. The contract will see SenSen rollout
Read More
Already facilitating 2 million medical appointments between medical professionals and patients, health tech company 1st Group (ASX: 1ST) is set to significantly grow its network with the launch of telehealthclinics.com.au – a dedicated site for booking medical appointments to be conducted via teleconference. Whilst COVID-19 has significantly heightened public interest in telehealth, 1st Group has
Read More
Under new management, medtech company Respiri (ASX: RSH) is poised to enter the lucrative SaaS revenue market by leveraging their asthma screening device to partner with Phenix Healthcare, whose patients will be able to monitor their condition using Respiri’s wheezo device. The agreement will give Phenix Healthcare’s patients diagnosed with asthma an option to monitor
Read More
Biotech company Genetic Signatures (ASX: GSS) is poised to play a major role in flattening the curve of coronavirus cases in Australia after the Therapeutics Goods Association (TGA) approved their SARS-CoV-2 Detection Kit for sale in Australia. Regulatory approval in Australia follows authorisation which was granted in Europe 10 days ago with Genetic Signatures able
Read More
With only one company set to list this month, it appears that the volatility that surrounds the ASX is prompting some companies to delay listing until some degree of normality in financial markets is restored. One company brave enough to face the current environment is Atomo Diagnostics Limited (Proposed ASX: AT1). The Sydney-based medical diagnostics
Read More
As the world battles the coronavirus pandemic, G Medical (ASX: GMV) has secured authorisation from the Food and Drug Administration to sell their Prizma smartphone attachment direct to customers without the need for a prescription, rocketing the company’s share price. Prizma, a smartphone attachment which can monitor a user’s vital signs, can play a vital
Read More
Prior to COVID-19 bringing attention to the value of telehealth, HeraMED (ASX: HMD) has been building digital infrastructure to revolutionise the maternal healthcare market with their screening and remote midwife platform which is preparing to now enter the lucrative U.S market. The expansion into the world’s most lucrative healthcare market, valued at USD $111 billion
Read More
Medtech company RhinoMed (ASX: RNO) will soon be significantly increasing its product shelf space in the United States having secured a distribution deal with CVS for its new over-the-counter (OTC) sleep aid product – Pronto Sleep. With the company forecasting the sleep aids market to reach $66.3 billion by 2021, RhinoMed’s interest focuses on OTC
Read More
